Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
Explore our Spectacular Science
Our scientists are building the medicines of tomorrow, marrying the best of biology and technology to revolutionize how we target and treat serious diseases.
Solving the human body’s most complex mysteries
Following the science leads to unexpected breakthroughs and diverse areas of study.Therapeutic Research Areas
Developing new medicines for serious diseases
A primarily ‘homegrown’ pipeline of potential medicines for dozens of diseases.Our Clinical Pipeline
35 years of challenges and triumphs
Our story is unusual, with remarkable consistency of leadership and purpose in our efforts to accelerate the drug discovery and development process.More About Us
Explore our clinical trials
The discoveries never stop as we work to help people with serious diseases. Clinical trials allow us to carefully test and collect data about investigational products before they can be approved for use. Learn more about our clinical trials or find a relevant one near you.
Doing well by doing good
Through responsible business practices and with the highest standards of integrity,
we rise to any challenge with characteristic drive and a focus on scientific innovation.
Our next generation of responsibility goals span three areas:
Moving at pandemic speed
We’re applying our novel technologies to respond swiftly to public health infectious disease outbreaks like Ebola, MERS and COVID-19.Rapid Response Efforts
Heroes of tomorrow
Alumni of Regeneron’s STEM programs and competitions have won National Medals of Science, Fields Medals and Nobel Prizes. Our goal? Equip the next generation to keep the accolades, and the groundbreaking science, coming.Our Stem Programs